Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Priovant Therapeutics' Lisraya (brepocitinib) wins first FDA approval as targeted TYK2/JAK1 inhibitor tablet for dermatomyositis
Small molecule, autoimmune, TYK2/JAK1 inhibitor, dermatomyositis, first-in-class - Read more

FDA approves Eli Lilly's Mounjaro (tirzepatide) GLP-1/GIP agonist for cardiovascular risk reduction in type 2 diabetes
Small molecule, cardiovascular, metabolic, GLP-1/GIP agonist, type 2 diabetes, tirzepatide - Read more

FDA approves Gilead Sciences' Bixlenvo (bictegravir/lenacapavir), integrase/capsid inhibitor pill for virologically suppressed human immunodeficiency virus patients
Small molecule, infectious disease, HIV, integrase inhibitor, capsid inhibitor, antiretroviral therapy - Read more

J&J's Icotyde wins China approval for moderate-to-severe plaque psoriasis treatment
Small molecule, autoimmune, oral therapy, psoriasis, TYK2 inhibitor - Read more

HUTCHMED's ATLED (fanregratinib) wins NMPA approval for FGFR2-fusion intrahepatic cholangiocarcinoma following Ph2 success
Small molecule, cancer, FGFR inhibitor, cholangiocarcinoma, FGFR2 fusion - Read more

Genentech, DualityBio partner on ADC-resistant cancer treatments, $45M upfront, $1B+ milestones
Licensing deal, oncology, antibody-drug conjugate, drug discovery, milestone payments - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Cytokinetics' Myqorzo (aficamten) shows Ph3 landmark benefits in non-obstructive hypertrophic cardiomyopathy, spurring FDA approval bid
Small molecule, cardiovascular, cardiac myosin inhibitor, hypertrophic cardiomyopathy, aficamten - Read more

Generate Bio's GB-0895 (anti-TSLP antibody) shows Ph1 biomarker reductions in chronic obstructive pulmonary disease
Antibody, respiratory disease, monoclonal antibody, COPD, asthma, TSLP target - Read more

Roche's Vabysmo (faricimab) shows sustained Ph3b/4 two-year efficacy in polypoidal choroidal vasculopathy, a neovascular age-related macular degeneration subtype
Antibody, ophthalmology, monoclonal antibody, age-related macular degeneration, Ang-2/VEGF-A inhibition, faricimab - Read more

Moderna plans $2B convertible notes offering, funding oncology business and debt repayment
Oncology, mRNA, cancer vaccine, clinical-stage, personalized medicine - Read more

AusperBio closes $120M Series C to advance chronic hepatitis B oligonucleotide therapeutics
Infectious disease, oligonucleotide, hepatitis B, clinical-stage, siRNA - Read more

Bristol Myers Squibb invests $173M to build second radiopharmaceutical manufacturing plant in Indiana
Radiopharmaceutical, oncology, major transaction, operational - Read more

Revolution Medicines' Rasonque pancreatic cancer drug poised for blockbuster status at $477K annually
Small molecule, oncology, revenue impact, competitive - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

BioXcel Therapeutics files bankruptcy, Teva Pharmaceuticals named stalking horse bidder for $57.5M upfront, $67.5M milestones
Acquisition, neurological, small molecule, milestone payments, bankruptcy - Read more

Deutsche Bank downgrades Novo Nordisk to sell, citing growth concerns and Ziltivekimab trial failure
Small molecule, obesity, competitive, financial - Read more

PhRMA's Medicare drug price negotiation lawsuit rejected by Fifth Circuit appeals court
PhRMA, drug pricing, regulatory, competitive - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here